首頁 › 慢性骨髓單核細胞白血病 › 德克薩斯州 › Houston
Houston, TX 的 慢性骨髓單核細胞白血病 臨床試驗
16 項針對 慢性骨髓單核細胞白血病 的研究正在 Houston（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
招募中2 期
- The University of Texas MD Anderson Cancer Center, Houston
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
招募中2 期
- M D Anderson Cancer Center, Houston
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
招募中2 期歡迎健康志工
- MD Anderson Cancer Center, Houston
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
招募中2 期
- M D Anderson Cancer Center, Houston
Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
招募中2 期
- MD Anderson Cancer Center, Houston
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
招募中2/3 期歡迎健康志工
- M D Anderson Cancer Center, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
招募中1/2 期
- M D Anderson Cancer Center, Houston
Personalized NK Cell Therapy in CBT
招募中2 期
- M D Anderson Cancer Center, Houston
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
招募中1/2 期
- The University of Texas M. D. Anderson Cancer Center, Houston
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
招募中2 期
- M D Anderson Cancer Center, Houston
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
招募中1 期
- M D Anderson Cancer Center, Houston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
招募中2/3 期
- MD Anderson Cancer Center, Houston
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
招募中1/2 期
- M D Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
招募中2 期
- MD Anderson, Houston
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
招募中1 期
- MD Anderson Cancer Center, Houston
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
招募中1 期
- MD Anderson Cancer Center, Houston
其他城市的 慢性骨髓單核細胞白血病 試驗
- Seattle, WA10 項研究
- Boston, MA7 項研究
- Mountain View, CA6 項研究
- Baldwin Park, CA6 項研究
- Rochester, MN6 項研究
- New York City, NY6 項研究
- Durham, NC5 項研究
- Miami, FL4 項研究
- Tampa, FL4 項研究
- Birmingham, AL4 項研究
- Columbus, OH4 項研究
- Atlanta, GA4 項研究
Houston 的其他研究
- 非小細胞肺癌145 項研究
- 乳癌126 項研究
- 癌症（所有類型）121 項研究
- 轉移性癌症104 項研究
- 大腸直腸癌102 項研究
- 卵巢癌89 項研究
- 急性髓系白血病85 項研究
- 肺癌78 項研究
- 前列腺癌76 項研究
- 子宮內膜癌68 項研究
- 胰臟癌61 項研究
- 黑色素瘤59 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。